Immune cells take on brain cancer in first human test
NCT ID NCT05651178
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new treatment for people with a rare and hard-to-treat type of lymphoma that has spread to the brain or spinal cord. The therapy uses the patient's own immune cells, modified to target two markers (CD19 and CD22) on cancer cells, and is given through a vein and directly into the spinal fluid. The main goals are to check safety and see if the treatment can shrink tumors, with 10 adults enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can lifestyle choices after a stroke extend life and prevent a second one?
- What happens years after CAR-T therapy? a study aims to find out
- Engineered immune cells take on tough lymphomas
- Promising drug may shrink brain tumors in relapsed lymphoma
- Brain cancer breakthrough? CAR t cells injected directly into fluid around brain in new trial
- Experimental pill plus chemo takes aim at Hard-to-Treat brain lymphoma